Pfizer’s tilrekimig meets primary endpoint in Phase II atopic dermatitis study

Pfizer has reported positive Phase II results for tilrekimig, an investigational trispecific antibody being developed for adults with moderate to severe atopic dermatitis.

The study met its primary endpoint, with all evaluated doses of tilrekimig producing a statistically significant increase in the proportion of patients achieving at least a 75% improvement in Eczema Area and Severity Index, known as EASI 75, at week 16 compared with placebo.

The findings were presented at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna.

Tilrekimig, also known as PF 07275315, is designed to simultaneously target three signalling pathways involved in type 2 inflammation.

The antibody binds with high affinity to interleukin 4, interleukin 13 and thymic stromal lymphopoietin, or TSLP.

Pfizer said the approach is intended to block both upstream and downstream drivers of inflammation, potentially allowing broader control of the inflammatory pathways involved in atopic dermatitis.

The treatment has also been designed with an extended half life of approximately 37 days, which could support once monthly administration.

Michael Vincent, MD, PhD, Chief Inflammation and Immunology Officer at Pfizer, said the Phase II findings support the potential of tilrekimig as a next generation biologic for inflammatory disease.

He said the efficacy and tolerability observed in the study provide further validation for simultaneously targeting multiple inflammatory pathways.

Pfizer has already advanced tilrekimig into Phase III development for atopic dermatitis and asthma.

The company is also progressing a Phase IIb and III programme evaluating the therapy in chronic obstructive pulmonary disease.

Eric Simpson, MD, MCR, from the Department of Dermatology at Oregon Health and Science University, said treatment for moderate to severe atopic dermatitis has increasingly shifted from broad immunosuppression towards therapies that target specific biological pathways.

He noted that despite these advances, some patients continue to experience persistent itching and extensive skin involvement.

Simpson said the week 16 findings for tilrekimig were encouraging at this stage of clinical development and that the treatment’s tolerability profile supports further evaluation in larger patient populations.

Atopic dermatitis is a chronic inflammatory skin condition commonly associated with itching, redness and skin lesions.

Pfizer said the disease can be driven by several inflammatory signals, creating an opportunity for therapies capable of targeting more than one pathway simultaneously.

---

---

Related Topics and Keywords

atopic dermatitis, clinical trials, dermatology, eczema, inflammation, Pfizer, pharma news, tilrekimig, Trispecific Antibody